Abstract
In a commercial claims database analysis, <0.5% of patients with inflammatory bowel disease or rheumatoid arthritis developed an invasive fungal infection (IFI) within 1 year of initiating tumor necrosis factor-alpha therapy. Histoplasmosis was the most common IFI type. Overall IFI incidence varied based on region, underlying conditions, and use of certain immunosuppressive medications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 364-366 |
| Number of pages | 3 |
| Journal | Clinical Infectious Diseases |
| Volume | 80 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 15 2025 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2024 Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Keywords
- TNF-α inhibitors
- histoplasmosis
- inflammatory bowel disease
- invasive fungal infections
- rheumatoid arthritis
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, U.S. Gov't, P.H.S.
Fingerprint
Dive into the research topics of 'Incidence and Risk Factors for Invasive Fungal Infections in Patients Initiating Tumor Necrosis Factor-Alpha Inhibitors for Inflammatory Bowel Disease and Rheumatoid Arthritis'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS